Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7398-7404

  Petty, W Jeffrey ^a   Miller, Antonius A ^a   McCoy, Thomas P ^a   Gallagher, Patricia E ^a   Tallant, E Ann ^a   Torti, Frank M ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7]; PLACENTAL GROWTH FACTOR; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD TOXICITY; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIAL NEUROPATHY; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; EMBOLISM; FATIGUE; FEMALE; GINGIVA DISEASE; HUMAN; HYPOCALCEMIA; LUNG CANCER; MALE; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; ORTHOSTATIC HYPOTENSION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SARCOMA; SOLID TUMOR; STROKE; THROMBOSIS; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANGIOTENSIN I; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 73149102795     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1957     Document Type: Article

References (33)

1. Ferrario CM, Averill DB, Brosnihan KB, et al. Regulation of cardiovascular control mechanisms by angiotensin-(1-7) and angiotensin converting enzyme 2. In: Carey R, editor. Hypertension and hormonal mechanisms. 2007, p. 43-59.
2. Bader M, Ganten D. Update on tissue reninangiotensin systems. JMol Med 2008;86:615-21.
3. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens 2009;18:33-9.
4. Santos RAS, Ferreira AJ, Silva ACS. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physio 2008;93:519-27.
5. Santos RAS, Simoes E, Silva AC, et al. Angiotensin-( 1-7) is an endogenous ligand for the G-protein coupled receptor mas. Proc Natl Acad Sci U S A 2003;100:8258-63.
6. Freeman EJ, Chisolm GM, Ferrario CM, et al. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996;28:104-8.
7. Strawn WB, Ferrario CM, Tallant EA. Angiotensin-( 1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999;33:207-11.
8. Langeveld B, Van Gilst WH, Gio RA, et al. Angiotensin-( 1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005;45:138-41.
9. Gallagher PE, Tallant EA. Inhibition of lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004;25:2045-52.
10. Menon J, Soto-Pantoja DR, Callahan MF, et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007;67:2809-15.
11. Soto-Pantoja DR, Menon J, Gallagher PE, et al. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009;8:1676-83.
12. Soto-Pantoja DR, Petty WJ, Gallagher PE, et al. Angiotensin-(1-7) inhibits triple negative tumor growth through the inhibition of angiogenesis and a reduction in placental growth factor PIGF. 2008.
13. Rodgers KE, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 2006;57:559-68.
14. Kohara K, Tabuchi Y, Senanayake P, et al. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides 1991;12:1135-41.
15. Merrill DC, Karoly M, Chen K, et al. Angiotensin-( 1-7) in normal and preeclamptic pregnancy. Endocrine 2002;18:239-45.
16. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
17. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-9.
18. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75.
19. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007;6:524-31.
20. Loges S, Schmidt T, Carmeliet P. Antimyeloangiogenic therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53.
21. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
22. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
23. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-76.
24. Tallant EA, Lu X, Weiss RB, et al. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension 1997;29:388-93.
25. Tallant EA, Menon J, Soto-Pantoja D, et al. Angiotensin peptides and cancer. In: Kastin AJ, editor. Handbook of Biologically Active Peptides. 2006, p. 459-65.
26. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008;29:1675-84.
27. Khakoo AY, Sidman RL, Pasqualini R, et al. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008;68:9112-5.
28. Herr D, Rodewald M, Fraser HM, et al. Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 2008;109:418-25.
29. Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996;14:799-805.
30. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-84.
31. Pahor M, Guralnik JM, Salive ME, et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-9.
32. Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997;349:525-8.
33. van der Knaap R, Siemes C, et al. Reninangiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008;112:748-57.